It has never been a better time for life sciences start-ups to raise money from venture sources. In 2017, according to data compiled by Informa Pharma Intelligence, venture capitalists invested a total of $19.7 billion in the sector across the globe – some $15.1 billion allocated to 512 biopharma-focused opportunities while $4.6 billion was invested in 107 medtech businesses. Europe’s share of the global take was nearly $4 billion, more than double what it was in 2013.
With new funds being raised and non-European investors looking for bargains, the prospects for European biopharma, medtech and digital health companies going forward looks fairly robust. (See Exhibit 1.) However,...